ArticleiScience2025
Campus-based genomic surveillance uncovers early emergence of a future dominant A(H3N2) influenza clade.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Post-Pandemic Genomic Diversity and Lineage Turnover of Influenza Viruses in Mexico During 2022-2023.Viruses · 2026Article
- Genome sequence of influenza virus strain A/Ust-Kamenogorsk/972/2023 (H3N2) from Kazakhstan.Microbiology resource announcements · 2026Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
We conducted genomic surveillance during the 2022-2023 northern hemisphere influenza season at a university in the southwestern US to assess how local diversity and evolution compared to national trends. We identified 100 positive samples (19%) from clinical swabs collected at a student health clinic and observed a dominance of subtype A(H3N2) which was consistent nationally for that season. However, we found stark differences when examining H3 clades, including an early dominance of 3C.2a1b.2a.2a.3a.1 variants contrasting from country level data in which 3C.2a1b.2a.2b variants were most abundant. We found known H3 amino acid substitutions in epitope sites and estimated vaccine effectiveness to be 0.13-0.48 which aligns with national estimates for that season. Importantly, 3C.2a1b.2a.2a.3a.1 became the dominant H3 clade nationally in 2023-2024 and 2024-2025, highlighting the potential for localized genomic surveillance in semi-closed, highly dense university settings and its potential for early insight of seasonal influenza diversity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.